Meeting Sum y. TB Alliance’s Stakeholders Association (SHA) held its annual meeting on Tuesday, ober 23, ahead of e 49 Union World Conference on Lung Heal in e Hague, Ne erlands. In e wake of e United Nations High-Level Meeting (HLM) on TB, a WHO rapid communication on changes to MDR-TB treatment, key milestones in TB Alliance’s development of e el BPaL and . , · Stakeholders Association Meeting. e Stakeholders Association (SHA) of e TB Alliance held its annual meeting on Tuesday, ober , ahead of e 48 Union World Conference on Lung Heal in Guadalajara, Mexico. Today, e development of new drugs for all forms of tuberculosis (TB) is at e forefront of efforts to end what is now e world’s deadliest infectious disease. On e heels of a year full of clinical advances and pivotal trial results, TB Alliance held its annual Stakeholders Association meeting in Barcelona, Spain on ober 27, ahead of e Union World Conference on Lung Heal. Nearly 0 key stakeholders attended e meeting to hear updates from TB Alliance, to discuss progress and opportunities to capitalize on e recent momentum in TB drug development . Stakeholders Association Meeting. TB Alliance held its annual Stakeholders Association meeting in Cape Town, Sou Africa on ember 1, ahead of e 46 Union World Conference on Lung Heal. is year, more an 130 key stakeholders attended e meeting to hear updates from TB Alliance, partners and stakeholders and to discuss exciting progress as well as challenges in e development and delivery of impactful TB drug regimens. e TB Alliance held its annual Stakeholders Association meeting in Paris, France on ober 28, ahead of e Union World Conference on Lung Heal. 90 participants attended to hear updates from e TB Alliance and discuss challenges and exciting new opportunities in e coming mon s and years. e meeting was presided over by Karl Hofmann, of PSI, e newly elected President of e Stakeholders Association and a member of e TB Alliance . III. TB CAB meeting wi e TB Alliance Carl Mendel’s Presentation [Note: product development information be outdated] Dr. Carl Mendel, Senior Vice President for Research and Development at e Global Alliance for TB Drug Development (TB Alliance), centered his presentation on e TB Alliance’s. TB Alliance is a not-for-profit organization dedicated to e discovery, development and delivery of better, faster-acting and affordable tuberculosis drugs at are available to ose who need em. A New Treatment Accelerating e Pace. STAKEHOLDER ENGAGEMENT STRATEGY CST Discussion Document Ottawa, Canada 11-12, 2008 DRAFT * * Target for Stakeholder Management around e Change Initiative By AGM – A free PowerPoint PPT presentation (displayed as a Flash slide show) on PowerShow.com - . MMV's 14 Stakeholder meeting brought toge er respected malaria research and public heal experts from Indonesia and e global malaria community as well as funding partners. It provided a platform for ese key stakeholders to discuss challenges and e latest advances in . Beginning of e meeting. Introduction of participants. One minute’s silence in remembrance of people who died before ey could receive treatment. Beginning of presentation My name is Stephanie Seidel, I represent e organization TB-Alliance (hereinafter – TBA). My colleague, Sarah Cook-Scalise will also be present at is call. USAID TB Technical Assistance Model e 19, Overview TA in e Context of USG TB Strategy Accomplishments and Approach of TB Strategy USAID TA Model * USAID TB Funding Trends 1998– Funding Level (Millions US $) * FY funds including all accounts * By , TB prevalence in 27 USAID-supported countries reased by 40. EDCTP Stakholder Meeting Tuberculosis Paris - ober 28, TUBERCULOSIS: REMAINING CHALLENGES Pr Jean-François DELFRAISSY. Director: ANRS & IMMI/AVIESAN. e French Alliance for Life and Heal Sciences: Aviesan Created in . stakeholder at large. It includes:. FAQs on e ree I's for HIV/TB for heal workers and communities 2. Glossary to define scientific terms 3. Congregate settings examples to highlight e impact of TB in settings outside of heal facilities 4. Posters to promote e adoption of e ree I’s for HIV/TB. 26, · Toge er, Covid-19 and TB pose a deadly, dual reat - a syndemic at feeds on social inequities and poverty. Tremendous catch-up work, advocacy, and funding will be . 28, · e Technical Advisor, MDR TB will represent ACTB in PMDT at national and subnational technical meetings and must build good rapport wi partners and stakeholders. S/he will be accountable for ensuring highest level of compliance wi ad conditions, organizational policies and procedures, and acceptable standards. 15, · TBEC was formed in by a group of TB patients from e EECA countries as a response to address two major concerns. First, e spread of resistant forms of TB (Multi-Drug Resistant TB and Extremely Drug-Resistant TB) in several countries of e European Region and e concentration of about a quarter of e global burden in e region. Long-neglected field of tuberculosis Founded in 2000 at meeting in Sou Africa Presentation will include Pretomanid –investigational drug developed by TB Alliance. 13, · e CR gives independent advice and feedback to e SHA and TB Alliance on all matters relating to TB drug research and development, and e introduction of new TB regimens. e CR is a voice for TB patients, participants in TB research, survivors, affected communities and advocates. Meetings Annual meeting. e annual meeting of e Child and Adolescent TB Working Group took place on Wednesday 30 ober in Hyderabad, India just prior to e 50 Union Conference and was attended by over 1 participants. e annual meeting provides a forum for exchange of global developments and country experiences. e meeting started wi a report from e vice chair on e. TB Drug Development - e Global Alliance for TB Drug Development, presented in a session on Perspectives From Global Public-Private Partnerships as part of an Add-On Seminar entitled Emerging Strategies and Structures in Global Heal Partnerships, Licensing Executives Society Annual Meeting, Phoenix, AZ (2005). 04, · An overview of TB Alliance's progress in developing new treatment regimens for tuberculosis. is video premiered at e Annual Meeting of TB Alliance's Stakeholders . 18, · TB CAB releases document outlining key considerations regarding pretomanid in anticipation of FDA public advisory committee meeting on e TB Alliance's new drug application for pretomanid. In ch , e U.S. Food and Drug Administration (FDA) accepted a new drug application for pretomanid, a drug candidate developed by e TB Alliance. TB Alliance Stakeholders Meeting Feedback Survey Question Title *. Please choose one of e following: I attended e recent Annual TB Alliance Stakeholders Meeting in e Hague, Ne erlands on ober 23, Quality of Presentations Quality of. 30, · On 29 y , advocates sent an open letter to a group of stakeholders meeting in Italy, including donors and government representatives, to raise considerations related to pretomanid access and transparency, and concerns regarding e lack of community representation at e meeting. Fur er investments in pretomanid should be made responsibly, and include terms at promote . 1 ENGAGING STAKEHOLDERS FOR RETOOLING TB CONTROL ENGAGING STAKEHOLDERS FOR RETOOLING TB CONTROL. INTRODUCTION e Stop TB Partnership’s Global Plan to Stop TB (2006-)1 describes e principal strategies at will be used for TB . Presentation of credentials to HE State Counsellor Call for action to ‘bend e curve to end TB’ in Sou East Asia - at recent Regional Ministerial Meeting Stakeholders meeting on Joint External Evaluation of International Heal Regulations H.E Dr Myint Htwe, Union Minister of Heal, giving e opening address at e. During e TB Alliance Stakeholder’s meeting, TB CARE I’s Program Director, Maarten van Cleeff, was anked for his service and valuable contributions to e TB Alliance, not only as e President of e Stakeholders Association but also as a Board Member. His ree-year term as Chair of e Stakeholders Association ended in ember . 12, · New York —TB Alliance, a not-for-profit organization leading e development of new, improved and affordable tuberculosis (TB) treatments, today announced at its Stakeholders Association (SHA) has elected Mitchell ren as its president, a position at entails a seat on TB Alliance’s Board of Directors. An accomplished leader and advocate, ren brings extensive . e objectives of e stakeholder meeting on malaria were to: Review e current status and barriers to progress in e field of malaria research. Identify e key research areas where EDCTP support can have maximum impact. Highlight opportunities for European and African collaboration (Nor -Nor and Nor -Sou) at EDCTP can facilitate. Previous annual meetings, events and news items Annual Meeting. e annual meeting of e Child and Adolescent TB working group took place on Monday 9 ober in Kigali, Rwanda in con ction wi e WHO AFRO annual review and planning meeting of reproductive, maternal, newborn, child and adolescent heal and nutrition programme managers in e East and Sou ern . TB Alliance, New York, USA Rob Aarnoutse PharmD, PhD Radboudumc, Nijmegen, e Ne erlands. 5 • Meeting Reports • Workshop Presentations • Webcasts INFECTIOUS DISEASES ONLINE. 9 experts and work toge er wi o er important stakeholders to achieve e. submitted by e Global Alliance for TB Drug Development, Inc., proposed as part of a combination regimen wi bedaquiline and linezolid in adults for e treatment of pulmonary extensively drug. 04, · Community and Stakeholder Engagement (CSE) streng ens relationships between researchers and local communities, and helps to ensure at study participants, eir families, key community stakeholders and o ers who be affected by or at risk have an opportunity to partner in e development and implementation of research efforts. 18, · TB in e News Solid Organ Transplant–Transmitted Tuberculosis Linked to a Community Outbreak — California, •Case of donor-derived TB disease •limitations in determining e TB status of organ donors rough medical evaluation or interviewing. •Au ors suggest reviewing organ donors medical records from high-risk environments, such as jails, to reveal additional TB risk . • Communicate wi key scientific stakeholders in e organization, requiring a high level of professionalism. • Manage/maintain/update multiple internal calendars and contacts.Title: Research And Development . e Stakeholders Association plays an integral role in shaping e work of TB Alliance, said Mel Spigelman, MD, president and CEO of TB Alliance. We are pleased to welcome Mitchell's leadership. e meeting was attended by over 180 participants representing a broad range of stakeholders including paediatricians, NTP managers and childhood TB focal points from e NTP, Maternal and Child Heal representatives, technical and financial partners, community TB representatives, and WHO staff from headquarters, Regional and Country offices. 12, · Guadalajara, Jalisco, Mexico - On e eve of e 48 Union World Conference on Lung Heal, being held in Guadalajara, ober 11-14, e Global Alliance for TB Drug Development (TB Alliance) announced e ongoing Phase-1 clinical studies for two new drugs for TB treatment it developed.. Bo compounds have proceeded rough early pre-clinical development and were . Global TB ket estimated. Q1 : PmRN endorses pediatric TB regulatory pa way. Q1 : WHO PQ approval. : Final products available in e ket. : Project Launch. Q1 : Global Stakeholders Meeting. Q2 : Dosage guidelines for children 5kg submitted to WHO PQ. Q4 : MOU signed wi first manufacturer. As Microbiology Consultant to TB Alliance, I: as well as scientific publications and presentations. stakeholder meetings, and follow up visits. as well as remotely, by developing scopes of Title: Microbiology Consultant at TB . 27, · Since its inception, e Tuberculosis Trials Consortium (TBTC) has undertaken nine major trials and 15 sub-studies. e completed TBTC studies have resulted in 25 publications in peer-reviewed journals, as well as over 0 presentations, posters, and abstracts at major medical or scientific meetings. TB Alliance Overview 3 •TB is a leading cause of dea among children worldwide and children are susceptible to e most severe and fatal forms of e disease • e ket for pediatric medicines is broken and needs repair and requires: –Better estimates of how many children get TB . ra er an because ey represent donor stake-holders. For e Global Alliance and MMV, ere is also an annual stakeholder’s meeting, equivalent to a companyshareholdermeeting,atwhich econcerns and viewpoints of stakeholders can be voiced. Since e partnerships are stand-alone and independent organizations, ey are accountable for. Feb 12, · NEW YORK, Feb. 12, /PRNewswire/ TB Alliance has appointed Dr. Daniel Everitt to e position of Vice President and Chief Medical Officer. In is role, Dr. Everitt will lead TB Alliance's development planning for lead drug candidates and el regimens and oversee e planning, design, and direction of all clinical trials. I represent TB Alliance at donor meetings and project kick-off meetings, ensuring a collaborative environment is created and nurtured over e course of each project.Title: Senior Specialist, External Affairs . Apr 18, · NEW YORK and HERTFORDSHIRE, England and PITTSBURGH, April 18, /PRNewswire/ Non-profit drug developer, TB Alliance, and pharmaceutical company, Mylan N.V. (NASDAQ: MYL), today announced a global collaboration to make e experimental drug pretomanid accessible for use in two investigational drug regimens for pulmonary tuberculosis (TB).. TB, a . Tuberculosis (TB) is preventable, treatable and curable. About 30 million people are going to get TB preventive treatment (TPT) by 2022. TB can not only be prevented, diagnosed and treated, but.